Dataset Information

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.

ABSTRACT:

Background

Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May-June 2020 and 7.1% in August-September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India.

Methods

The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged ≥10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated.

Results

Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein, and 7436 (26%) had IgG antibodies against either the N protein or the S1-RBD protein. Weighted and assay-characteristic-adjusted seroprevalence against either of the antibodies was 24.1% [95% confidence interval (CI) 23.0-25.3%]. Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5-27.8%).

Conclusions

Nearly one in four individuals aged ≥10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020.

SUBMITTER: Murhekar MV

PROVIDER: S-EPMC8132496 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.

Murhekar Manoj V MV Bhatnagar Tarun T Thangaraj Jeromie Wesley Vivian JWV Saravanakumar V V Kumar Muthusamy Santhosh MS Selvaraju Sriram S Rade Kiran K Kumar C P Girish CPG Sabarinathan R R Turuk Alka A Asthana Smita S Balachandar Rakesh R Bangar Sampada Dipak SD Bansal Avi Kumar AK Chopra Vishal V Das Dasarathi D Deb Alok Kumar AK Devi Kangjam Rekha KR Dhikav Vikas V Dwivedi Gaurav Raj GR Khan S Muhammad Salim SMS Kumar M Sunil MS Laxmaiah Avula A Madhukar Major M Mahapatra Amarendra A Rangaraju Chethana C Turuk Jyotirmayee J Yadav Rajiv R Andhalkar Rushikesh R Arunraj K K Bharadwaj Dinesh Kumar DK Bharti Pravin P Bhattacharya Debdutta D Bhat Jyothi J Chahal Ashrafjit S AS Chakraborty Debjit D Chaudhury Anshuman A Deval Hirawati H Dhatrak Sarang S Dayal Rakesh R Elantamilan D D Giridharan Prathiksha P Haq Inaamul I Hudda Ramesh Kumar RK Jagjeevan Babu B Kalliath Arshad A Kanungo Srikanta S Krishnan Nivethitha N NN Kshatri Jaya Singh JS Kumar Alok A Kumar Niraj N Kumar V G Vinoth VGV Lakshmi G G J Naga GGJN Mehta Ganesh G Mishra Nandan Kumar NK Mitra Anindya A Nagbhushanam K K Nimmathota Arlappa A Nirmala A R AR Pandey Ashok Kumar AK Prasad Ganta Venkata GV Qurieshi Mariya Amin MA Reddy Sirasanambatti Devarajulu SD Robinson Aby A Sahay Seema S Saxena Rochak R Sekar Krithikaa K Shukla Vijay Kumar VK Singh Hari Bhan HB Singh Prashant Kumar PK Singh Pushpendra P Singh Rajeev R Srinivasan Nivetha N Varma Dantuluri Sheethal DS Viramgami Ankit A Wilson Vimith Cheruvathoor VC Yadav Surabhi S Yadav Suresh S Zaman Kamran K Chakrabarti Amit A Das Aparup A Dhaliwal R S RS Dutta Shanta S Kant Rajni R Khan A M AM Narain Kanwar K Narasimhaiah Somashekar S Padmapriyadarshini Chandrasekaran C Pandey Krishna K Pati Sanghamitra S Patil Shripad S Rajkumar Hemalatha H Ramarao Tekumalla T Sharma Y K YK Singh Shalini S Panda Samiran S Reddy D C S DCS Bhargava Balram B

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20210519

<h4>Background</h4>Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May-June 2020 and 7.1% in August-September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India.<h4>Methods</h4>The third serosurvey was conducted in the same 70 districts as the first and second serosurv ...[more]

PMID: 34022338

Similar Datasets

Project description:BackgroundIndia began COVID-19 vaccination in January 2021, initially targeting healthcare and frontline workers. The vaccination strategy was expanded in a phased manner and currently covers all individuals aged 18 years and above. India experienced a severe second wave of COVID-19 during March-June 2021. We conducted a fourth nationwide serosurvey to estimate prevalence of SARS-CoV-2 antibodies in the general population aged ≥6 years and healthcare workers (HCWs).Methods and findingsWe did a cross-sectional study between 14 June and 6 July 2021 in the same 70 districts across 20 states and 1 union territory where 3 previous rounds of serosurveys were conducted. From each district, 10 clusters (villages in rural areas and wards in urban areas) were selected by the probability proportional to population size method. From each district, a minimum of 400 individuals aged ≥6 years from the general population (40 individuals from each cluster) and 100 HCWs from the district public health facilities were included. The serum samples were tested for the presence of IgG antibodies against S1-RBD and nucleocapsid protein of SARS-CoV-2 using chemiluminescence immunoassay. We estimated the weighted and test-adjusted seroprevalence of IgG antibodies against SARS-CoV-2, along with 95% CIs, based on the presence of antibodies to S1-RBD and/or nucleocapsid protein. Of the 28,975 individuals who participated in the survey, 2,892 (10%) were aged 6-9 years, 5,798 (20%) were aged 10-17 years, and 20,285 (70%) were aged ≥18 years; 15,160 (52.3%) participants were female, and 21,794 (75.2%) resided in rural areas. The weighted and test-adjusted prevalence of IgG antibodies against S1-RBD and/or nucleocapsid protein among the general population aged ≥6 years was 67.6% (95% CI 66.4% to 68.7%). Seroprevalence increased with age (p < 0.001) and was not different in rural and urban areas (p = 0.822). Compared to unvaccinated adults (62.3%, 95% CI 60.9% to 63.7%), seroprevalence was significantly higher among individuals who had received 1 vaccine dose (81.0%, 95% CI 79.6% to 82.3%, p < 0.001) and 2 vaccine doses (89.8%, 95% CI 88.4% to 91.1%, p < 0.001). The seroprevalence of IgG antibodies among 7,252 HCWs was 85.2% (95% CI 83.5% to 86.7%). Important limitations of the study include the survey design, which was aimed to estimate seroprevalence at the national level and not at a sub-national level, and the non-participation of 19% of eligible individuals in the survey.ConclusionsNearly two-thirds of individuals aged ≥6 years from the general population and 85% of HCWs had antibodies against SARS-CoV-2 by June-July 2021 in India. As one-third of the population is still seronegative, it is necessary to accelerate the coverage of COVID-19 vaccination among adults and continue adherence to non-pharmaceutical interventions.

Project description:BackgroundBy August 2021, the COVID-19 pandemic has been less severe in sub-Saharan Africa than elsewhere. In Malawi, there have been three subsequent epidemic waves. We therefore aimed to describe the dynamics of SARS-CoV-2 exposure in Malawi.MethodsWe measured the seroprevalence of anti-SARS-CoV-2 antibodies amongst randomly selected blood transfusion donor sera in Malawi from January 2020 to July 2021 using a cross-sectional study design. In a subset, we also assessed in vitro neutralisation against the original variant (D614G WT) and the Beta variant.ResultsA total of 5085 samples were selected from the blood donor database, of which 4075 (80.1%) were aged 20-49 years. Of the total, 1401 were seropositive. After adjustment for assay characteristics and applying population weights, seropositivity reached peaks in October 2020 (18.5%) and May 2021 (64.9%) reflecting the first two epidemic waves. Unlike the first wave, both urban and rural areas had high seropositivity in the second wave, Balaka (rural, 66.2%, April 2021), Blantyre (urban, 75.6%, May 2021), Lilongwe (urban, 78.0%, May 2021), and Mzuzu (urban, 74.6%, April 2021). Blantyre and Mzuzu also show indications of the start of a third pandemic wave with seroprevalence picking up again in July 2021 (Blantyre, 81.7%; Mzuzu, 71.0%). More first wave sera showed in vitro neutralisation activity against the original variant (78% [7/9]) than the beta variant (22% [2/9]), while more second wave sera showed neutralisation activity against the beta variant (75% [12/16]) than the original variant (63% [10/16]).ConclusionThe findings confirm extensive SARS-CoV-2 exposure in Malawi over two epidemic waves with likely poor cross-protection to reinfection from the first on the second wave. The dynamics of SARS-CoV-2 exposure will therefore need to be taken into account in the formulation of the COVID-19 vaccination policy in Malawi and across the region. Future studies should use an adequate sample size for the assessment of neutralisation activity across a panel of SARS-CoV-2 variants of concern/interest to estimate community immunity.

Dataset Information

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.

Background

Methods

Results

Conclusions

Publications

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets